Eyenovia Inc. (NASDAQ:EYEN) and Motif Bio plc (NASDAQ:MTFB) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Motif Bio plc||N/A||0.00||13.98M||-2.02||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for Eyenovia Inc. and Motif Bio plc.
Table 2 provides us the return on assets, net margins and return on equity of both businesses.
|Net Margins||Return on Equity||Return on Assets|
|Motif Bio plc||0.00%||0%||0%|
Institutional and Insider Ownership
Institutional investors held 10% of Eyenovia Inc. shares and 7.46% of Motif Bio plc shares. Eyenovia Inc.’s share held by insiders are 2.1%.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Motif Bio plc||3.83%||-81.17%||-75.8%||-76.6%||-78.75%||-71.17%|
For the past year Eyenovia Inc. had bullish trend while Motif Bio plc had bearish trend.
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.